NUVECTIS PHARMA INC's ticker is and the CUSIP is 67080T108. A total of 14 filers reported holding NUVECTIS PHARMA INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,752,717 | -11.6% | 291,134 | +9.5% | 0.00% | – |
| Q2 2023 | $4,247,030 | +60.8% | 265,938 | +32.0% | 0.00% | – |
| Q1 2023 | $2,640,786 | +79.8% | 201,433 | +2.9% | 0.00% | – |
| Q4 2022 | $1,468,718 | +665.0% | 195,829 | +623.7% | 0.00% | – |
| Q3 2022 | $192,000 | -26.4% | 27,061 | +16.4% | 0.00% | – |
| Q2 2022 | $261,000 | – | 23,257 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ronit Capital LLP | 550,000 | $4,076,000 | 5.10% |
| Virtu Financial LLC | 11,365 | $84,000 | 0.01% |
| WELLS FARGO & COMPANY/MN | 20 | $0 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 14,822 | $109,000 | 0.00% |
| MILLENNIUM MANAGEMENT LLC | 42,160 | $312,000 | 0.00% |
| BlackRock Inc. | 7,872 | $59,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 1,750 | $13,000 | 0.00% |
| UBS Group AG | 141 | $1,000 | 0.00% |